Latest Breaking News On - Arrivent biopharma - Page 9 : comparemela.com

StockWatch: IPO Revival? CG Oncology, ArriVent Raise a Combined $555M

StockWatch: IPO Revival? CG Oncology, ArriVent Raise a Combined $555M
genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.

Hong kongUnited statesNewtown squareAnnovis bioPaul knightArrivent biopharmaJacob thaysenCalmette guerinLuke sergottMaria maccecchiniKyle stanfordPacific biosciencesBarclays capitalThermo fisherGoldman sachsSotera health

Week In Review: Arrivent BioPharma Raises $175M In IPO For In-Licensings From China

Week In Review: Arrivent BioPharma Raises $175M In IPO For In-Licensings From China
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

United statesMacau generalAsia pacificAllist pharmaLily asiaJiuzhou pharmaJiangsu alphamab biopharmaSagimet biomedMohammed elamineGuangdong hong kongSagimet biosciencesZhejiang jiuzhou pharmaArrivent biopharmaRaybow life sciencesChemical liquid creamCollagen clear crystal premium serum

Cancer drugmaker ArriVent follows on CG s heels with $175M IPO

BioPharma

Takeda exkivityDizal pharmaArrivent biopharmaJohnson rybrevantBlueprint pharmaceuticalsDive briefVent biopharmaBiopharma diveWall streetAlto neuroscienceKyverna therapeuticsAarvik therapeutics

ArriVent brings in $175M for biotech s second IPO of the year

ArriVent brings in $175M for biotech s second IPO of the year
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Arrivent biopharmaAlto neuroscience

ArriVent s Nasdaq Debut Nabs $175M as Signs Indicate an Opening IPO Window

ArriVent BioPharma will apply the IPO cash toward furmonertinib, which the biotech says could offer advantages over Takeda Pharmaceutical and Johnson & Johnson drugs that address the same lung cancer target. It’s the second biotech IPO of this week, following CG Oncology.

Arrivent biopharmaJohnson rybrevantAllist pharmaNewtown squareFederal reservePennsylvania based arriventShanghai based allistAlto neuroscienceMetagenomi technologiesWeight lossMedical devicesHealthcare innovationMedcity newsMedcity newsSan franciscoLife sciences